Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1096 AL 1110

The path to next-generation disease-modifying immunomodulatory combination therapies in Alzheimer's disease

Sarazin M, Lagarde J, El Haddad I, de Souza LC, Bellier B, Potier MC, Bottlaender M, Dorothée G.

Nat Aging. 2024 Jun;4(6):761-770. doi: 10.1038/s43587-024-00630-2. Epub 2024 Jun 5.

Biomarkers and Target-Specific Small-Molecule Drugs in Alzheimer's Diagnostic and Therapeutic Research: From Amyloidosis to Tauopathy

Sheng L, Bhalla R.

Neurochem Res. 2024 Sep;49(9):2273-2302. doi: 10.1007/s11064-024-04178-w. Epub 2024 Jun 6.

Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer's Disease

Taylor J, Jaros M, Chen C, Harrison J, Hilt D.

J Alzheimers Dis. 2024;100(1):139-150. doi: 10.3233/JAD-231456.

Employing Informatics Strategies in Alzheimer's Disease Research: A Review from Genetics, Multiomics, and Biomarkers to Clinical Outcomes

Bao J, Lee BN, Wen J, Kim M, Mu S, Yang S, Davatzikos C, Long Q, Ritchie MD, Shen L.

Annu Rev Biomed Data Sci. 2024 Aug;7(1):391-418. doi: 10.1146/annurev-biodatasci-102423-121021. Epub 2024 Jul 24.

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease

Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND, Sheardova K, Kesslak P, Shen L, Zhu X, Albayrak A, Paul J, Schaefer JF, Power A, Tolar M.

Drugs. 2024 Jul;84(7):811-823. doi: 10.1007/s40265-024-02067-8. Epub 2024 Jun 20.

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease

Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME.

Neurobiol Dis. 2024 Sep;199:106575. doi: 10.1016/j.nbd.2024.106575. Epub 2024 Jun 22.

Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates

Hroudová J, Fišar Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111069. doi: 10.1016/j.pnpbp.2024.111069. Epub 2024 Jun 23.

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas RG, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH.

Alzheimers Res Ther. 2024 Jul 5;16(1):151. doi: 10.1186/s13195-024-01490-z.

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

Korologou-Linden R, Kalsi J, Kafetsouli D, Olawale A, Iwata A, Wingfield D, Mummery D, Hayhoe B, Robinson O, Majeed A, Middleton LT.

J Prev Alzheimers Dis. 2024;11(4):897-902. doi: 10.14283/jpad.2024.83.

A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya JR, Zielinski M, Venkatraman V, Goodenowe D, Hofmeister K, Zhang J, Ahlem C, Reading C, Palumbo J, Pourat B, Kuhn T, Jordan S.

Medicine (Baltimore). 2024 Jul 26;103(30):e39027. doi: 10.1097/MD.0000000000039027.

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care

Palmqvist S, Tideman P, Mattsson-Carlgren N, Schindler SE, Smith R, Ossenkoppele R, Calling S, West T, Monane M, Verghese PB, Braunstein JB, Blennow K, Janelidze S, Stomrud E, Salvadó G, Hansson O.

JAMA. 2024 Oct 15;332(15):1245-1257. doi: 10.1001/jama.2024.13855.

A genetic and proteomic comparison of key AD biomarkers across tissues

Marsh TW, Western D, Timsina J, Gorijala P, Yang C, Pastor P, Liu M, Morris JC, Bateman RJ, Schindler SE, Sung YJ; Dominantly Inherited Alzheimer Network; Cruchaga C.

Alzheimers Dement. 2024 Sep;20(9):6423-6440. doi: 10.1002/alz.14139. Epub 2024 Jul 30.

Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?

Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P, López-Ortiz S, Martín-Hernández J, Gabelle A, Caruso G, Malaguti M, Melchiorri D, Santos-Lozano A, Imbimbo C, Heneka MT, Caraci F.

J Neuroinflammation. 2024 Jul 30;21(1):187. doi: 10.1186/s12974-024-03163-y.

Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update

Garnier-Crussard A.

Alzheimers Res Ther. 2024 Aug 1;16(1):177. doi: 10.1186/s13195-024-01547-z.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias